Skip to main content
. 2011 May 3;15(1):1–10. doi: 10.1159/000325746

Table 3.

Use of trastuzumab among breast cancer patients diagnosed between 1998–2007

SEER Stage HER2 positivea, (%)
HER2 discordantb, (%)
HER2 negative/equivocal/unknown, (%)
1998–2004 2005–2007 2004–2007 1998–2007
In situ 0/1c (0) 0/0 (0) 0/0 (0) 2/537 (<1)
Localized 4/220 (2) 35/79 (44) 1/31 (3) 12/1815 (<1)
Regional 20/123 (16) 28/41 (68) 0/23 (0) 10/619 (1.6)
Distant metastasis 11/22 (50) 8/10 (80) 1/2 (50) 2/68 (3)
Total 35/366 (9) 71/130 (55) 2/56 (4) 26/3039 (0.8)
a

Patients were defined as HER2 positive if they had a positive HER2 test result by either FISH or IHC or both, but not discordant HER2 results.

b

Patients were defined as HER2 discordant if the IHC test was positive and the FISH test was negative (n = 55) or the other way around (n = 1).

c

The ratio in each cell refers to the number of patients who received trastuzumab divided by the total number of patients in that cell.